ClinicalTrials.gg
CompletedNCT00988247Updated Dec 3, 2021Results posted

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

A Phase 3 interventional study of Beclomethasone dipropionate and Placebo Nasal Aerosol in Rhinitis, Allergic, Perennial, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 34 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-12-03.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
529
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Rhinitis, Allergic, Perennial with a site in United States — none open to participants now, 1 under way, 1 of them phase 3. Rhinitis, Allergic, Perennial · United States.

Enrollment
16th of 57
529 · median 301
Started
2009
with 4 others
Phase 3
33 of 60
none open now
Registered
39th of 60
by date
Lead sponsor
4 of 60
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 60 studies in Rhinitis, Allergic, Perennial with a site in United States, this one is the 16th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2009, is one of 33 in phase 3, and was the 39th registered.

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

Browse Rhinitis, Allergic, Perennial studies →

Open to participants now

None of the 60 studies in Rhinitis, Allergic, Perennial with a site in United States is open now. The open studies under Rhinitis, Allergic, Perennial, anywhere →

Who these studies take

Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 60 studies in Rhinitis, Allergic, Perennial with a site in United States as a file.
02

Study summary

Subjects with perennial allergic rhinitis will be randomized to 320 mcg of beclomethasone dipropionate (BDP) using a hydrofluoroalkane (HFA) propellant or placebo as a nasal aerosol. The subjects will be followed for safety and efficacy for a period of 30 or 52 weeks. BDP HFA is a steroid which is currently FDA approved for the treatment of asthma. BDP-HFA should be safe and effective as a "dry" nasal aerosol which may be preferred by some patients.

03

Conditions studied

  • Rhinitis, Allergic, Perennial

Keywords

  • Rhinitis, Allergic, Perennial
  • BDP-HFA
  • Hay fever
  • Allergic rhinitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects, 12 years of age or older as of the Screening Visit (SV)
  • General good health, and free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the subject at increased risk during the study
  • A history of PAR to a relevant perennial allergen for a minimum of two years immediately preceding the study Screening Visit (SV). The PAR must have been of sufficient severity to have required treatment (either continuous or intermittent) in the past, and in the investigator's judgment is expected to require treatment throughout the entire study
  • A demonstrated sensitivity to at least one allergen known to induce PAR through a standard skin prick test. A positive test is defined as a wheal diameter at least 3 mm larger than the diluent control wheal for the skin prick test. Documentation of a positive result 12 months prior to Screening Visit (SV) is acceptable
  • Other criteria apply

Exclusion criteria

Exclusion Criteria:

  • History of physical findings of nasal pathology, including nasal polyps or other respiratory tract malformations, recent nasal , nasal trauma, including nasal piercing, or surgery and atrophic rhinitis or rhinitis medicamentosa (all within the last 60 days prior to Screening Visit [SV])
  • Participation in any drug study within the 30 days preceding the Screening Visit (SV) or planned participation in another investigational drug study at any time during this study
  • History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, chronic sinusitis, or influenza within the 14 days preceding the Screening Visit (SV) or development of a respiratory infection during the Run-In Period
  • Active asthma requiring treatment with inhaled or systemic and/or routine use of β-agonists and any controller drugs (e.g., theophylline, leukotriene antagonists). History of intermittent use (less than or equal to 3 uses per week) of inhaled short acting beta-agonists prior to the Screening Visit (SV) is acceptable.
  • Other criteria apply

Randomization Criteria

  • Subject continues to be in general good health, meeting the selection criteria
  • Subject has a minimum subject-reported reflective TNSS of an average of 5 (out of a possible 12) on the last 7 days during the Run-In Period
  • The subject-reported scores for rhinorrhea or nasal congestion must be an average of 2 or greater during the last 7 days of the Run-In Period
  • Each subject must have adequately completed the electronic AR Assessment Diary (failure is defined as missing the diary entry on more than 2 calendar days during the last 7 days of the Run-In Period)
  • Other criteria apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
529 participants (actual)

Study arms

  • Experimental
    BDP HFA 320 µg/day

    During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.

    Drug: Beclomethasone dipropionate

  • Placebo comparator
    Placebo

    During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.

    Drug: Placebo Nasal Aerosol

Interventions

  • Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site).

    Also known as: QNASL(TM)

  • DrugPlacebo Nasal Aerosol

    Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 30 Weeks

    Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 24-hours (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.

    Time frame: Baseline (Days -6 to 0), Day 1 to Week 30

Secondary outcomes

  1. Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 30 Weeks

    Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 10 minutes (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.

    Time frame: Baseline (Days -6 to 0), Day 1 to Week 30

  2. Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 52 Weeks

    Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 24-hours (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.

    Time frame: Baseline (Days -6 to 0), Day 1 to Week 52

  3. Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 52 Weeks

    Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 10 minutes (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.

    Time frame: Baseline (Days -6 to 0), Day 1 to Week 52

  4. Change From Baseline to Week 30 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline

    The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. Week 30 scores were compared to baseline scores. A negative change score indicates improvement.

    Time frame: Day 0 (Baseline) and Week 30

  5. Change From Baseline to Week 52 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline

    The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. Week 52 scores were compared to baseline scores. A negative change score indicates improvement.

    Time frame: Day 0 (Baseline) and Week 52

07

Results

Posted May 23, 2012

Participant flow

A total of 857 patients were screened and 775 patients were enrolled in the study and participated in the Run-in Period. Of the 775 enrolled patients, 529 were randomized to study treatment.

Participant flow — Overall Study
MilestoneBDP HFA 320 µg/DayPlacebo
Started418111
Safety population415111
Intent to treat population414110
Completed33585
Not completed8326
Withdrew: Adverse event173
Withdrew: Withdrawal by subject4413
Withdrew: Pregnancy12
Withdrew: Lost to follow-up112
Withdrew: Protocol violation45
Withdrew: Sponsor requested withdrawal31
Withdrew: Other30

Outcome measures

PrimaryChange From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 30 Weeks

Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 24-hours (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.

Time frame:
Baseline (Days -6 to 0), Day 1 to Week 30
Reported as:
Least squares mean · units on a scale
Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 30 Weeks
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 30 Weeks-3.4 ± 0.11-2.4 ± 0.22
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = <0.001 · Ls mean treatment diff from placebo]: -0.97 · 95% CI -1.5 to -0.5The repeated measures ANCOVA included covariate adjustment for baseline, treatment, week and the treatment by week interaction.
SecondaryChange From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 30 Weeks

Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 10 minutes (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.

Time frame:
Baseline (Days -6 to 0), Day 1 to Week 30
Reported as:
Least squares mean · units on a scale
Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 30 Weeks
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 30 Weeks-2.9 ± 0.11-2.0 ± 0.21
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = <0.001 · Ls mean treatment diff from placebo]: -0.96 · 95% CI -1.4 to -0.5The repeated measures ANCOVA included covariate adjustment for baseline, treatment, week and the treatment by week interaction.
SecondaryChange From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 52 Weeks

Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 24-hours (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.

Time frame:
Baseline (Days -6 to 0), Day 1 to Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 52 Weeks
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 52 Weeks-3.7 ± 0.12-2.6 ± 0.23
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = <0.001 · Ls mean treatment diff from placebo]: -1.09 · 95% CI -1.6 to -0.6The repeated measures ANCOVA included covariate adjustment for baseline, treatment, week and the treatment by week interaction.
SecondaryChange From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 52 Weeks

Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 10 minutes (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.

Time frame:
Baseline (Days -6 to 0), Day 1 to Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 52 Weeks
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 52 Weeks-3.1 ± 0.11-2.0 ± 0.22
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = <0.001 · Ls mean treatment diff from placebo]: -1.10 · 95% CI -1.6 to -0.6The repeated measures ANCOVA included covariate adjustment for baseline, treatment, week and the treatment by week interaction.
SecondaryChange From Baseline to Week 30 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline

The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. Week 30 scores were compared to baseline scores. A negative change score indicates improvement.

Time frame:
Day 0 (Baseline) and Week 30
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 30 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline to Week 30 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline-2.2 ± 0.09-1.9 ± 0.19
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = 0.143 · Treatment difference: -0.30 · 95% CI -0.7 to 0.1ANCOVA with treatment, baseline and pooled center in the model.
SecondaryChange From Baseline to Week 52 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline

The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. Week 52 scores were compared to baseline scores. A negative change score indicates improvement.

Time frame:
Day 0 (Baseline) and Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 52 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline
units on a scaleBDP HFA 320 µg/DayPlacebo
Change From Baseline to Week 52 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline-2.0 ± 0.14-1.5 ± 0.30
Statistical analysis
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = 0.130 · Treatment difference: -0.49 · 95% CI -1.1 to 0.1ANCOVA with treatment, baseline and pooled center in the model.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BDP HFA 320 µg/Day—8/415 (1.9%)216/415 (52%)
Placebo—3/111 (2.7%)37/111 (33.3%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBDP HFA 320 µg/DayPlacebo
Ovarian cystReproductive system and breast disorders0/4151/111
ArthralgiaMusculoskeletal and connective tissue disorders0/4151/111
Viral infectionInfections and infestations0/4151/111
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/4150/111
NephrolithiasisRenal and urinary disorders1/4150/111
Intraocular pressure increasedInvestigations1/4150/111
Bladder injuryInjury, poisoning and procedural complications1/4150/111
MenorrhagiaReproductive system and breast disorders1/4150/111
Pelvic adhesionsReproductive system and breast disorders1/4150/111
PneumothoraxRespiratory, thoracic and mediastinal disorders1/4150/111
Most frequent other events
Most frequent other events
EventBDP HFA 320 µg/DayPlacebo
NasopharyngitisInfections and infestations67/41514/111
EpistaxisRespiratory, thoracic and mediastinal disorders44/4152/111
Upper respiratory tract infectionInfections and infestations43/4157/111
SinusitisInfections and infestations34/4158/111
HeadacheNervous system disorders28/4156/111

Baseline characteristics

Age, Continuous
Age, Continuous(years)BDP HFA 320 µg/DayPlaceboTotal
Mean37.4 ± 13.635.7 ± 12.937.1 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)BDP HFA 320 µg/DayPlaceboTotal
Female28666352
Male12844172
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BDP HFA 320 µg/DayPlaceboTotal
Hispanic or Latino451257
Not Hispanic or Latino36998467
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BDP HFA 320 µg/DayPlaceboTotal
American Indian or Alaska Native729
Asian13114
Native Hawaiian or Other Pacific Islander303
Black or African American631477
White34197438
Unknown or Not Reported101
Body mass index
Body mass index(kg/m^2)BDP HFA 320 µg/DayPlaceboTotal
Mean28.8 ± 6.728.4 ± 6.728.7 ± 6.7
08

Study locations

34 sites
  • Teva Clinical Sudy Site
    Oxford, Alabama 36203, United States
  • Teva Clinical Study Site
    Encinitas, California 92024, United States
  • Teva Clinical Study Site
    Huntington Beach, California 92647, United States
  • Teva Clinical Study Site
    San Diego, California 92120, United States
  • Teva Clinical Study Site
    Stockton, California 95207, United States
  • Teva Clinical Study Site
    Colorado Springs, Colorado 80907, United States
  • Teva Clinical Study Site
    Atlanta, Georgia 30342, United States
  • Teva Clinical Study Site
    Stockbridge, Georgia 30281, United States
  • Teva Clinical Study Site
    Normal, Illinois 61761, United States
  • Teva Clinical Study Site
    Lenexa, Kansas 66215, United States
  • Teva Clinical Study Site
    Overland Park, Kansas 66210, United States
  • Teva Clinical Study Site
    Metairie, Louisiana 70006, United States
  • Teva Clinical Study Site
    Wheaton, Maryland 20902, United States
  • Teva Clinical Study Site
    Ypsilanti, Michigan 48197, United States
  • Teva Clinical Study Site
    Minneapolis, Minnesota 55402, United States
  • Teva Clinical Study Site
    Plymouth, Minnesota 55441, United States
  • Teva Clinical Study Site
    Bozeman, Montana 59718, United States
  • Teva Clinical Study Site
    North Syracuse, New York 13212, United States
  • Teva Clinical Study Site
    Rochester, New York 14618, United States
  • Teva Clinical Study Site
    Rockville Center, New York 11570, United States
  • Teva Clinical Study Site
    High Point, North Carolina 27262, United States
  • Teva Clinical Study Site
    Cincinnati, Ohio 45231, United States
  • Teva Clinical Study Site
    Sylvania, Ohio 43560, United States
  • Teva Clinical Study Site
    Eugene, Oregon 97401, United States
  • Teva Clinical Study Site
    Bethlehem, Pennsylvania 18020, United States
  • Teva Clinical Study Site
    Collegeville, Pennsylvania 19426, United States
  • Teva Clinical Study Site
    Dallas, Texas 75231, United States
  • Teva Clinical Study Site
    El Paso, Texas 79903, United States
  • Teva Clinical Study Site
    Houston, Texas 77054, United States
  • Teva Clinical Study Site
    Kerrville, Texas 78028, United States
  • Teva Clinical Study Site
    San Antonio, Texas 78229, United States
  • Teva Clinical Study Site
    Vancouver, Washington 98664, United States
  • Teva Clinical Study Site
    Greenfield, Wisconsin 53228, United States
  • Teva Clinical Study Site
    West Allis, Wisconsin 53227, United States
09

References and documents

Publications

  • Meltzer EO, Jacobs RL, LaForce CF, Kelley CL, Dunbar SA, Tantry SK. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc. 2012 May-Jun;33(3):249-57. doi: 10.2500/aap.2012.33.3571. PubMed 22737708 ↗
  • Meltzer EO, Jacobs RL, LaForce CF, Dorinsky PM, Kelley L, Dunbar SA, Tantry SK. . BDP HFA Nasal Aerosol 320 µg Once Daily Is Safe and Effective in the Treatment of Nasal Symptoms Associated With Perennial Allergic Rhinitis. Ann Allergy Asthma Immunol 2011 (Supplement); 107(11):A118 - Poster presentation.
  • Carr W, Meltzer EO, Finn A, Dorinsky PM, Kelley L, Dunbar SA, Tantry SK. Effective nasal symptom relief and improvement in health-related quality of life in subjects with perennial allergic rhinitis following 6-week once-daily treatment with beclomethasone dipropionate hydrofluoroalkane nasal aerosol. J Allergy Clin Immunol 2012 (Supplement); 129:AB188 - Poster presentation
  • Gross GN, Settipane RA, Ford LB, Kelley L, Dunbar SA, Tantry SK, Dorinsky PM . Patient Satisfaction and Ease-of-Use of BDP HFA Nasal Aerosol Device in Subjects With Perennial Allergic Rhinitis. Ann Allergy Asthma Immunol 2011 (Supplement); 107(11):A119 - Poster presentation
  • Weinstein SF, Andrews CP, Shah SR, Chylack LT Jr, Tankelevich A, Ding Y, Tantry SK. Long-term efficacy and safety of once-daily treatment with beclomethasone dipropionate nasal aerosol. Allergy Asthma Proc. 2014 Jul-Aug;35(4):323-31. doi: 10.2500/aap.2014.35.3767. PubMed 24992552 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Feb 2011, 15 months.

Results were first posted in May 2012, 1 year 2 months after primary completion. A results delay was requested in Aug 2011.

Of 17 phase 3 interventional studies under Rhinitis, Allergic, Perennial, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 15 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2009
First posted
Oct 2, 2009
StartActual
Oct 31, 2009
Primary completionActual
Feb 28, 2011
CompletionActual
Feb 28, 2011
Results delay requested
Aug 25, 2011
Results first posted
May 23, 2012
Last update
Dec 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00988247
Responsible party
Sponsor
First posted
Oct 2, 2009
Start date
Oct 31, 2009
Primary completion
Feb 28, 2011
Completion
Feb 28, 2011
Results posted
May 23, 2012
Last update
Dec 3, 2021

Study contacts

Study Director
study director · Teva Branded

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion